FDA Approves First-In-Class Med for Parkinson's Disease

The FDA approved tavapadon, the first selective D1/D5 receptor agonist tablet for adults with Parkinson's disease, based on positive results from three pivotal phase 3 TEMPO trials showing improved motor function and increased daily on-time. Tavapadon offers a novel treatment targeting a different dopamine receptor class compared to existing therapies, potentially broadening management options.

This Wire brief sits within Fusion42's coverage of Drug Discovery, and 4 sources have reported it between 27 Sep 2026 and 29 Sep 2026.